# Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma

> **NCT06046482** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 4 (actual)

## Conditions studied

- Head Neck
- Squamous Cell Carcinoma of Head and Neck

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Magrolimab
- **DRUG:** cetuximab
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT06046482
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-11-28
- **Primary completion:** 2024-08-26
- **Final completion:** 2024-08-26
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Slow Accrual
- **Last updated:** 2025-10-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06046482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06046482, "Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06046482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*